MDT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Medtronic PLC (MDT) is not a strong buy for a beginner investor with a long-term horizon at this moment. The stock shows mixed signals, with weak technical indicators, cautious sentiment from Congress trading data, and declining financial performance in the latest quarter. While there are positive catalysts such as hedge fund buying and new product launches, the lack of strong upward momentum and recent analyst downgrades suggest a hold strategy for now.
The technical indicators are weak. The MACD is negative and expanding downward, RSI is neutral but leaning towards oversold, and moving averages are converging without a clear trend. The stock is trading near its support level (S1: 93.452), with resistance at 95.998, indicating limited upward momentum in the short term.
Hedge funds are significantly increasing their positions in MDT, with a 167.88% increase in buying over the last quarter.
Analysts highlight potential growth from new product launches in multi-billion-dollar markets.
The company continues to pay dividends, reflecting its commitment to shareholder returns.
Congress members have made four recent sale transactions, showing cautious sentiment.
Financial performance in Q3 2026 showed declining net income (-11.67% YoY) and EPS (-11.88% YoY), along with a drop in gross margin (-2.58% YoY).
Analysts have lowered price targets recently, with mixed ratings (Neutral and Buy).
In Q3 2026, revenue increased by 8.74% YoY to $9.017 billion, but net income dropped by 11.67% YoY to $1.143 billion. EPS also declined by 11.88% YoY to $0.89, and gross margin fell to 59.93% (-2.58% YoY). This indicates revenue growth but declining profitability and efficiency.
Analyst ratings are mixed. Some analysts, like Mizuho and Barclays, have positive outlooks with price targets of $125 and $118, respectively, citing growth potential from new products. However, others like JPMorgan and Baird have lowered price targets to $100, citing sustainability concerns for 2027 growth. The consensus reflects cautious optimism.
